BR112023019862A2 - Formulações de l-asparaginase - Google Patents
Formulações de l-asparaginaseInfo
- Publication number
- BR112023019862A2 BR112023019862A2 BR112023019862A BR112023019862A BR112023019862A2 BR 112023019862 A2 BR112023019862 A2 BR 112023019862A2 BR 112023019862 A BR112023019862 A BR 112023019862A BR 112023019862 A BR112023019862 A BR 112023019862A BR 112023019862 A2 BR112023019862 A2 BR 112023019862A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- asparaginase
- lbl
- lla
- treatable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 title abstract 3
- 108010024976 Asparaginase Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
formulações de l-asparaginase. a presente invenção refere-se a formulações estáveis, aquosas e não liofilizadas de l-asparaginase. também são fornecidos no presente documento métodos para usar tais formulações no tratamento de uma ou mais doenças, distúrbios ou condições (por exemplo, cânceres como leucemia linfoblástica aguda (lla) ou linfoma linfoblástico (lbl)) que são tratáveis por depleção de asparagina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171429P | 2021-04-06 | 2021-04-06 | |
| PCT/US2022/071562 WO2022217231A1 (en) | 2021-04-06 | 2022-04-05 | Formulations of l-asparaginase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019862A2 true BR112023019862A2 (pt) | 2023-11-07 |
Family
ID=81748398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019862A BR112023019862A2 (pt) | 2021-04-06 | 2022-04-05 | Formulações de l-asparaginase |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4319818A1 (pt) |
| JP (1) | JP2024515555A (pt) |
| KR (1) | KR20230165799A (pt) |
| CN (1) | CN117377494A (pt) |
| AR (1) | AR125301A1 (pt) |
| AU (1) | AU2022256071A1 (pt) |
| BR (1) | BR112023019862A2 (pt) |
| CA (1) | CA3213726A1 (pt) |
| CL (1) | CL2023002983A1 (pt) |
| CO (1) | CO2023014093A2 (pt) |
| WO (1) | WO2022217231A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| KR20230162139A (ko) * | 2016-06-01 | 2023-11-28 | 세르비에 아이피 유케이 리미티드 | 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법 |
| AU2020371963A1 (en) * | 2019-10-25 | 2022-05-26 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant L-asparaginase |
-
2022
- 2022-04-05 AR ARP220100846A patent/AR125301A1/es unknown
- 2022-04-05 BR BR112023019862A patent/BR112023019862A2/pt unknown
- 2022-04-05 EP EP22724215.3A patent/EP4319818A1/en active Pending
- 2022-04-05 CN CN202280032191.2A patent/CN117377494A/zh active Pending
- 2022-04-05 AU AU2022256071A patent/AU2022256071A1/en active Pending
- 2022-04-05 JP JP2023561628A patent/JP2024515555A/ja active Pending
- 2022-04-05 CA CA3213726A patent/CA3213726A1/en active Pending
- 2022-04-05 WO PCT/US2022/071562 patent/WO2022217231A1/en active Application Filing
- 2022-04-05 KR KR1020237037007A patent/KR20230165799A/ko unknown
-
2023
- 2023-10-05 CL CL2023002983A patent/CL2023002983A1/es unknown
- 2023-10-23 CO CONC2023/0014093A patent/CO2023014093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023014093A2 (es) | 2023-10-30 |
| CN117377494A (zh) | 2024-01-09 |
| AU2022256071A1 (en) | 2023-10-19 |
| AR125301A1 (es) | 2023-07-05 |
| EP4319818A1 (en) | 2024-02-14 |
| WO2022217231A1 (en) | 2022-10-13 |
| JP2024515555A (ja) | 2024-04-10 |
| CL2023002983A1 (es) | 2024-04-12 |
| KR20230165799A (ko) | 2023-12-05 |
| CA3213726A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
| EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| MX2018003351A (es) | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. | |
| BR112015022462A2 (pt) | inibidores de ido | |
| BR112015032595A2 (pt) | inibidores de ido | |
| BR112023000047A2 (pt) | Compostos de ureia tricíclicos como inibidores da v617f da jak2 | |
| CO2020010552A2 (es) | Compuestos | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| BR112017017349A2 (pt) | composto, composição, método para tratar um distúrbio | |
| MX2023001450A (es) | Composiciones y metodos para la inhibicion de la expresion de plp1. | |
| BR112021012829A2 (pt) | Composições e métodos para modular o crescimento capilar | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| BR112022023025A2 (pt) | Moduladores de htt para tratar doença de huntington | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| MX2023001538A (es) | Composiciones y metodos para inhibir la expresion de lpa. | |
| BR112022021562A2 (pt) | Partículas interferentes terapêuticas para o coronavírus | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| BR112021017661A2 (pt) | Uso de compostos 8,9-di-hidrocanabidiol | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| CO2022002616A2 (es) | Composiciones de trofinetida | |
| BR112023019862A2 (pt) | Formulações de l-asparaginase | |
| PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof |